| Dr Mirza A Kajani, MD | |
|
226 E College St, Suite B, Griffin, GA 30224-4348 | |
| (678) 987-1490 | |
| (678) 987-1491 |
| Full Name | Dr Mirza A Kajani |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 44 Years |
| Location | 226 E College St, Griffin, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306975651 | NPI | - | NPPES |
| 300052394 | Other | GA | TAX I.D. FOR OTHER INSURA |
| 000403147A | Medicaid | GA | |
| 102I100129 | Other | GA | PTAN |
| 202I100956 | Other | GA | PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 31955 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar Spalding Regional Hospital | Griffin, GA | Hospital |
| Piedmont Henry Hospital | Stockbridge, GA | Hospital |
| Northside Hospital | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aga Professional Services Llc | 3870768997 | 140 |
News Archive
Oxygen Biotherapeutics, Inc. today reported on the results of two University of Miami Miller School of Medicine studies involving the Company's third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.
Research by kinesiology investigator Dustin Hittel, PhD, has proven that muscle in extremely obese individuals produces large amounts of a protein called myostatin, which normally inhibits muscle growth-suggesting that for Type 2 diabetics, and the very obese, the task of getting healthy may be more difficult than initially thought.
No matter the mode of transportation, holiday travel holds special challenged for parents. Either you're stuck in an enormous security line at an airport filled with cranky people or hearing the constant stream of "are we there yet" from the back seat of the car. It's enough to make a Scrooge out of even the most Tiny Tim of us. For many families adding to the chaos is the reality that their child has a dangerous nut allergy.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
› Verified 3 days ago
| Entity Name | Aga, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124064118 PECOS PAC ID: 2365431350 Enrollment ID: O20040506000726 |
News Archive
Oxygen Biotherapeutics, Inc. today reported on the results of two University of Miami Miller School of Medicine studies involving the Company's third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.
Research by kinesiology investigator Dustin Hittel, PhD, has proven that muscle in extremely obese individuals produces large amounts of a protein called myostatin, which normally inhibits muscle growth-suggesting that for Type 2 diabetics, and the very obese, the task of getting healthy may be more difficult than initially thought.
No matter the mode of transportation, holiday travel holds special challenged for parents. Either you're stuck in an enormous security line at an airport filled with cranky people or hearing the constant stream of "are we there yet" from the back seat of the car. It's enough to make a Scrooge out of even the most Tiny Tim of us. For many families adding to the chaos is the reality that their child has a dangerous nut allergy.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
› Verified 3 days ago
| Entity Name | Aga Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063799120 PECOS PAC ID: 3870768997 Enrollment ID: O20111219000311 |
News Archive
Oxygen Biotherapeutics, Inc. today reported on the results of two University of Miami Miller School of Medicine studies involving the Company's third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.
Research by kinesiology investigator Dustin Hittel, PhD, has proven that muscle in extremely obese individuals produces large amounts of a protein called myostatin, which normally inhibits muscle growth-suggesting that for Type 2 diabetics, and the very obese, the task of getting healthy may be more difficult than initially thought.
No matter the mode of transportation, holiday travel holds special challenged for parents. Either you're stuck in an enormous security line at an airport filled with cranky people or hearing the constant stream of "are we there yet" from the back seat of the car. It's enough to make a Scrooge out of even the most Tiny Tim of us. For many families adding to the chaos is the reality that their child has a dangerous nut allergy.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mirza A Kajani, MD 226 E College St, Suite B, Griffin, GA 30224-4348 Ph: (678) 987-1490 | Dr Mirza A Kajani, MD 226 E College St, Suite B, Griffin, GA 30224-4348 Ph: (678) 987-1490 |
News Archive
Oxygen Biotherapeutics, Inc. today reported on the results of two University of Miami Miller School of Medicine studies involving the Company's third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.
Research by kinesiology investigator Dustin Hittel, PhD, has proven that muscle in extremely obese individuals produces large amounts of a protein called myostatin, which normally inhibits muscle growth-suggesting that for Type 2 diabetics, and the very obese, the task of getting healthy may be more difficult than initially thought.
No matter the mode of transportation, holiday travel holds special challenged for parents. Either you're stuck in an enormous security line at an airport filled with cranky people or hearing the constant stream of "are we there yet" from the back seat of the car. It's enough to make a Scrooge out of even the most Tiny Tim of us. For many families adding to the chaos is the reality that their child has a dangerous nut allergy.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
› Verified 3 days ago
Dr. Appaswamy M Gowda, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 230 W College St, Suite C, Griffin, GA 30224 Phone: 770-228-9020 Fax: 770-229-4063 | |
Jolina Pamela C Santos, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 604a S 8th St, Griffin, GA 30224 Phone: 678-248-2899 Fax: 770-233-4824 | |
Noor Ul Ain Munira Naz Qureshi, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 747 S 8th St Ste B, Griffin, GA 30224 Phone: 470-604-8250 Fax: 770-999-2814 | |
John R Dupre, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 604a S 8th St, Griffin, GA 30224 Phone: 770-227-1999 | |
Dr. Cyril Anara, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 601 S 8th St, Griffin, GA 30224 Phone: 770-229-6909 | |
Dr. Rosa Estiponia Clemente, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 415 S 8th St, Griffin, GA 30224 Phone: 770-228-5187 Fax: 770-228-9837 | |
Dr. James Orien Day Iii, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 231 Graefe St, Griffin, GA 30224 Phone: 770-227-1587 Fax: 770-227-1485 |